Loading stock data…
CAPR
$30.91-2.67 (-7.95%)
Market ClosedLast close May 1
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Capricor Therapeutics, Inc. in the Healthcare sector is trading at $30.91. The stock is currently 23% below its 52-week high of $40.37, remaining 73.5% above its 200-day moving average. Technical signals show neutral RSI of 35 and bearish MACD signal, explaining why CAPR maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 35) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$30.91
Potential Upside
5%
Whystock Fair Value$32.46
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the Un...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.02B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.48
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-8.99%
Volume
Today's trading volume
1.74M
Recent News
How Phase 3 HOPE-3 DMD Data And BLA Review At Capricor Therapeutics (CAPR) Has Changed Its Investment Story
Capricor Therapeutics recently presented data from its Phase 3 HOPE-3 trial of Deramiocel for Duchenne muscular dystrophy at the 2026 American Academy of Neurology meeting, highlighting statistically and clinically meaningful preservation of upper limb function supported by real-world video assessments of self-feeding ability. The combination of late-stage efficacy data and an ongoing Biologics License Application review with an August 22, 2026 PDUFA date underscores Deramiocel’s potential...
We're Not Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn
Just because a business does not make any money, does not mean that the stock will go down. For example, Capricor...
Capricor Therapeutics (CAPR) Reports Positive Phase 3 HOPE-3 Data and $318M 2025 Cash Balance
Capricor Therapeutics Inc. (NASDAQ:CAPR) is one of the best hot stocks to buy according to analysts. On March 12, Capricor Therapeutics presented new late-breaking data from its Phase 3 HOPE-3 clinical trial at the 2026 MDA Conference, highlighting the benefits of Deramiocel for Duchenne muscular dystrophy. Cardiac MRI results showed a reduction in myocardial fibrosis […]
Is It Too Late To Reassess Capricor Therapeutics (CAPR) After Its Recent 130% Surge?
If you are wondering whether Capricor Therapeutics at around US$30.50 is priced for its potential or already running ahead of itself, you are not alone. The stock has posted returns of 9.3% over the last 7 days, 26.0% over 30 days and 7.7% year to date, with a 1 year gain of 130.5% and a very large 3 year return that is more than 7x. This naturally raises questions about what is already baked into the price. Recent news around Capricor Therapeutics has centered on its progress in the...
Capricor Therapeutics Inc (CAPR) Q4 2025 Earnings Call Highlights: FDA Milestones and Financial ...
Capricor Therapeutics Inc (CAPR) advances with FDA acceptance for Jeremiasel, but faces revenue decline and increased expenses.